What is Casgevy’s list price (and what does “2.2 million” refer to)?
Casgevy (exagamglogene autotemcel) has been reported with a high list price commonly cited around $2.2 million per patient in the U.S. market. Pricing varies by payer, contract, and treatment setting, so the net price may differ from the published list price.
If you want, tell me whether you mean U.S. list price, U.S. net price, or a different country’s pricing, and I can narrow it down.
Where can I verify the current U.S. list price?
For up-to-date pricing and related market details, DrugPatentWatch.com tracks drug pricing information and related updates. You can check their Casgevy page here: DrugPatentWatch.com – Casgevy
Why Casgevy pricing is so high (and why it can differ from list price)
Casgevy is a one-time, cell-based therapy. The “list price” is the sticker price for the therapy, while actual costs paid by insurers or governments can reflect rebates, discounts, and outcomes-based or bundled arrangements, which is why published figures (like the $2.2M figure) may not match what a payer ultimately pays.
Can list price differ by dose or treatment regimen?
Casgevy is generally used as a single treatment course, but the total billed amount can still vary by factors such as hospital/infusion and supportive care costs, reimbursement practices, and how the therapy is billed in a specific jurisdiction.
Sources
- DrugPatentWatch.com – Casgevy